Edition:
United Kingdom

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

23.86USD
13 Dec 2018
Change (% chg)

$0.01 (+0.04%)
Prev Close
$23.85
Open
$23.86
Day's High
$23.89
Day's Low
$23.84
Volume
130,553
Avg. Vol
615,789
52-wk High
$23.94
52-wk Low
$2.86

Select another date:

Mon, Dec 3 2018

BRIEF-Endocyte - On Nov 30, Waiting Period With Respect To Filing Under Hart-Scott-Rodino Act Expired In Connection With Proposed Merger With Novartis AG

* ENDOCYTE SAYS ON NOV 30, 2018, WAITING PERIOD WITH RESPECT TO FILING UNDER HART-SCOTT-RODINO ACT EXPIRED IN CONNECTION WITH PROPOSED MERGER WITH NOVARTIS AG Source text: [https://bit.ly/2SogDFh] Further company coverage:

Deals of the day-Mergers and acquisitions

Oct 18 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday:

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

ZURICH Novartis is paying $2.1 billion (£1.6 billion) for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.

Novartis pushes deeper into nuclear medicine with $2.1 billion deal

ZURICH Novartis is paying $2.1 billion for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies.

UPDATE 2-Novartis pushes deeper into nuclear medicine with $2.1 bln deal

* Analysts say Q3 results take back seat to deal (Adds comments from CEO, shares, details throughout)

Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash

Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

UPDATE 1-Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash

Oct 18 Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday.

BRIEF-Novartis To Buy Endocyte In $2.1 Bln Deal

* NOVARTIS ANNOUNCES PLANNED ACQUISITION OF ENDOCYTE TO EXPAND EXPERTISE IN RADIOPHARMACEUTICALS AND BUILD ON COMMITMENT TO TRANSFORMATIONAL THERAPEUTIC PLATFORMS

Novartis to buy Endocyte for $2.1 billion in cash

Oct 18 Biopharmaceutical company Endocyte Inc said on Thursday that Novartis AG will acquire Endocyte in an all-cash deal for $24 per share, or a total equity value of about $2.1 billion.

BRIEF-Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion

* ENDOCYTE ENTERS INTO AGREEMENT TO BE ACQUIRED BY NOVARTIS AG FOR $2.1 BILLION

Select another date: